id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-354902-t9df8vhc	Kearns, Donovan G.	Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic	2020-06-10		.txt	text/plain	590	36	51	title: Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic 10 Dupilumab, an interleukin 4 alpha receptor antagonist that inhibits IL-4 and IL-13 signaling, is a 11 treatment for patients >12 years with moderate to severe atopic dermatitis (AD). In three randomized, placebo-controlled phase III clinical trials (SOLO 1, SOLO 2, and 18 CHRONOS), adults with moderate-to-severe AD received dupilumab (300 mg) weekly (qw), 19 3 Furthermore, in 28 all three trials, it was concluded that the rate of infection was not increased in dupilumab-treated 29 patients compared to placebo. Two Phase 3 Trials of Dupilumab versus 58 Placebo in Atopic Dermatitis Long-term management of 60 moderate-to-severe atopic dermatitis with dupilumab and concomitant topical 61 corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-62 controlled, phase 3 trial	./cache/cord-354902-t9df8vhc.txt	./txt/cord-354902-t9df8vhc.txt